Neonatal alloimmün trombositopeni
Loading...
Files
Date
2011-07-06
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Neonatal Alloimmün Trombositopeni (NAT) yenidoğan döneminde ağır trombositopeniye neden olan nadir bir hastalıktır. Anne ve bebek arasındaki trombosit antijen uyumsuzluğu sonucunda annede fetal trombositlere karşı gelişen antikorlar, fetusa geçerek intrauterin dönemden itibaren trombositopeniye yol açabilir. Klinik bulgular hafif ya da ağır olabilir. Olguların yaklaşık yarısı ilk gebelikte görülür. İzleyen gebeliklerde görülme sıklığı artar. Olay antikorların uzaklaşması ile kendini sınırlar. Ancak, gebelik süresince anne ve fetusun dikkatli ve yakından izlenmesi ve endikasyonu olduğu takdirde tedavinin hemen düzenlenmesi gerekir. Artmış mortalite ve morbiditesi nedeniyle erken tanınması, tedavi edilmesi ve ailenin sonraki gebeliklerdeki riskler hakkında bilgilendirilmesi önemlidir.
Neonatal alloimmune thrombocytopenia is a rare disease causing serious thrombocytopenia during neotatal period. Antibodies developed against fetal thrombocytes due to fetal-maternal platelet antigen incompatibility cause thrombocytopenia both in intrauterine period and afterwards. The clinical symptoms vary from mild to severe. Half of the cases occurs during first pregnancy. The recurrence risk increases in the subsequent pregnancies. The event is limited when the antibodies are cleared away. However, a careful close follow-up is needed both for the mothers and fetus/babies and the treatment should be immediately started when it is indicated. Early diagnosis, treatment and giving information to the parents about the risks of the subsuquent pregnancies are important issues due to increased morbidity and mortality of the disease.
Neonatal alloimmune thrombocytopenia is a rare disease causing serious thrombocytopenia during neotatal period. Antibodies developed against fetal thrombocytes due to fetal-maternal platelet antigen incompatibility cause thrombocytopenia both in intrauterine period and afterwards. The clinical symptoms vary from mild to severe. Half of the cases occurs during first pregnancy. The recurrence risk increases in the subsequent pregnancies. The event is limited when the antibodies are cleared away. However, a careful close follow-up is needed both for the mothers and fetus/babies and the treatment should be immediately started when it is indicated. Early diagnosis, treatment and giving information to the parents about the risks of the subsuquent pregnancies are important issues due to increased morbidity and mortality of the disease.
Description
Keywords
Neonatal alloimmün trombositopeni, Tanı, Tedavi, Neonatal alloimmune thrombocytopenia, Diagnosis, Treatment
Citation
Evim, M. S. ve Güneş, A. M. (2011). "Neonatal alloimmün trombositopeni". Güncel Pediatri, 9(2), 93-96.